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Smary We report the safety and efficacy of autologous bone marrow transplantation (ABMT) in 30
patients with high-grade non-Hodgkin's lymphoma (NHL) in first complete remission (CR1) following
remission induction chemotherapy. Two patients relapsed prior to ABMT. All patients were conditioned with
high-dose melphalan. In addition, ten received fractionated total body irradiation, one hemi-body irradiation
and four high-dose etoposide. Unmanipulated non-cryopreserved autologous marrow was reinfused within
56 h of harvesting. Engraftment occurred in all patients with a median of 11 days of neutropenia
(<0.5 x 1091'), a median requirement for platelet transfusion of 3 days and packed red cell transfusion of 2
units, with a median hospital stay of 18 days post transplant. There was no procedure-related mortality and
only minor morbidity was observed. Two patients relapsed at 1 and 2 months post transplantation, and one
patient died of carcinoma of the lung 33 months after transplantation. The remaining 25 patients remain alive,
well and in CR1 with a median follow-up of 44 months. The event-free survival at 3 years for all patients
considered for ABMT was 83%. We conclude that ABMT for high-grade NHL in CR1 with non-
cryopreserved marrow results in rapid haematological recovery without growth factor support. It is safe and is
associated with high survival when used as consolidation of CR in high-risk patients.
The outcome of treatment for high-grade non-Hodgkin's
lymphoma (NHL) has improved in recent years with the
adoption of more intensive chemotherapeutic regimens. Many
centres report complete response rates of 70-80% in high-
grade NHL (Armitage et al., 1986; Skarin, 1986; Coiffier et
al., 1989). When patients relapse the prognosis is poor,
although survival has improved with the development of
more aggressive chemotherapeutic salvage regimens. Dose
tolerance, limited by marrow toxicity, can be extended by the
use of autologous bone marrow transplantation (ABMT).
This approach has been used successfully in patients with
relapsed high-grade NHL, although the procedural morbidity
and mortality is substantial and relapse rates of around 50%
are common (Gribben et al., 1989; Petersen et al., 1990). We
have previously reported the lack of toxicity associated with
the use of ABMT in first remission in adult patients with
high-grade lymphoproliferative disorders (Carey et al., 1991).
The relatively disappointing long-term results with conven-
tional chemotherapy in high-risk, high-grade NHL en-
couraged us to investigate the use of early intensification
using ABMT following remission induction in this group of
patients. The aim was to assess whether early intensification
with minimal toxicity would help to sustain complete remis-
sion and lead to prolonged disease-free survival.
Patients and methods
Thirty patients (21 males, nine females) with high-risk, high-
grade NHL (Kiel classification) in CR1 were referred for
consideration of ABMT between January 1984 and December
1991. Median age for all patients was 38 years (range
16-58). Patient clinical details are given in Table I. All
patients received remission induction treatment according to
the Scotland and Newcastle Lymphoma Group (SNLG)
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NHL III protocol (Carey et al., 1991). This included six
cycles of chemotherapy utilising B-CHOP-M (bleomycin, cy-
clophosphamide, adriamycin, vincristine, prednisolone and
methotrexate) or B-CHOP-M alternating with PEEC-M
(methylprednisolone, etoposide, vindesine, chlorambucil and
methotrexate) as part of a randomised tnral of induction
therapy. Patients were offered intensification with ABMT
when one or more of the following high-risk features were
present:
1. stage IV disease;
2. bulk disease >10 cm;
3. multiple extranodal sites (> 2 sites);
4. NHL occurring after previous therapy for Hodgkin's
disease;
5. CNS involvement.
All histology was centrally reviewed by two pathologists
within the SNLG prior to entry to the programme, and each
patient was considered in-depth by the Lymphoma Group
transplant physicians in conference with the reviewing
pathologists and referring physicians.
Assessment ofrelapse risk status
At the time the study began objective assessments of relapse
risk were not available. Retrospectively the group of patients
in the study were assessed for relapse risk according to the
prognostic factor index developed on SNLG data by Hay-
ward et al. (1991). This index, subsequently validated
(Leonard et al., 1993), delineates a good-risk group with an
event-free survival of 54%, an intermediate-risk group with
an event-free survival of 31% and a worst-risk group with
11% event-free survival (Table I).
The application of the SNLG index to this patient cohort
indicated that seven patients had an index <2.0 (good prog-
nosis), six patients an index of 2.0-2.59 (intermediate prog-
nosis) and 17 an index >2.6 (poor prognosis). No patient
referred for consideration of ABMT declined the procedure,
and all patients gave fully informed consent. Two patients
relapsed prior to transplantation and were treated with sal-
vage chemotherapy. The median time to transplant from
diagnosis was 9 months (range 6-12) with remission induc-
tion chemotherapy taking approximately 5 months and local
radiotherapy another month in those patients with bulk
disease. In all patients bone marrow biopsy was performed
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Table I Risk coeffcients according to the SNLG index (Hayward et al., 1991)
Risk score
Performance status
I or 2 0.53
3 or4 1.3
Clinical stage 3 or 4 0.29 Good prognosis <2.0
B symptoms present 0.42 Add scores Intermediate 2.0-2.59
WCC abnormal (high or low) 0.42 Poor prognosis Ica 2.6
Liver involved 0.48
CNS involved 0.70
Each year of ageadded 0.023
Example: patient aged 50, performance status 2, stage IVB, no liver/CNS involved, WCC abnormal:
Risk = 50 x 0.023 + 0.53 + 0.29 + 0.42 + 0.42 = 2.81 = poor prognosis
Theapplication oftheSNLGindex tothispatientcohortindicated thatsevenpatients had anindex <2.0
(good prognosis), six patients an index of2.0-2.59 Cmtermediate prognosis) and 17 an index >2.6 (poor
prognosis).
2-4 weeks prior to ABMT to assess bone marrow cellularity
and remission status. All patients received high-dose mel-
phalan (HDM) conditioning, but those patients with features
associated with a high risk of CNS relapse (lymphoblastic
histology, multiple extranodal sites or marrow involvement at
diagnosis) also received fractionated total body irradiation
(TBI). As a result of our experience using high-dose etopo-
side (HDE) and HDM as conditioning for transplantation in
Hodgkin's disease (Taylor et al., 1993), the last four patients
in this study received HDM and HDE, as it was hoped that
this regimen might improve efficacy without increasing toxi-
city. Both melphalan and etoposide have a short half-life,
and it is possible to give sequential high doses of both drugs
and still utilise non-cryopreserved marrow rescue.
Autotransplantationprocedure
At the time of marrow harvest, patients were anaesthetised
and given 2,000-3,000 IU of sodium heparin intravenously.
Bone marrow was aspirated from the posterior iliac crests
into acid citrate dextrose anticoagulant in standard blood
transfusion collection packs, to give a median nucleated cell
dose of 3.2 x 10' perkg recipient weight (range 1.91-4.8).
The length of procedure including general anaesthetic was
less than 60min.
Harvested marrow was kept at 4-C for up to 56 h. Condi-
tioning proceeded with melphalan 3 mgkg- I body weight by
intravenous infusion immediately after drug reconstitution
using a container protected from light. Patients receivimg
etoposide were given a total dose of 1,600mgm-2 as a
continuous intravenous infusion over 20 h. TBI was given to
ten patients to a total dose of 1,050cGy in three fractions
each of 350 cGy. The three fractions were given over 24h to
allow reinfusion of the unmanipulated non-cryoprved
marrow within 56 h of harvesting, using a standard blood
transfusion giving set.
Supportive care
Patients were nursed in single rooms and received standard
supportive care during haematological recovery. All patients
were given acyclovir, oral nystatin and oral amphotericin
prophylactically. Multiple donor platelet transfusions were
given to maintain the platelet count about 20 x 10 1-' and
red cell transfusions to maintain the haemoglobin above
lOgdl-'. All cellular blood products for transfusion were
irradiated and CMV antibody negative. Three patients (2, 10,
13) received recombinant granulocyte colony-stimulating fac-
tor (rG-CSF) as part of a large multinational trial of rG-CSF
therapy following ABMT.
Reudts
Haematological reconstitution
Neutrophil and platelet recovery occurred without delay in
all patients. The rate of recovery did not vary with the
differing conditioning therapies. Median number of days of
neutropenia (<0.5 x l091-') was 11 (range 7-20). Median
number of days to a platelet count of >50 x I0'-I was 22
(range 13-49), but patients required transfusion of platelet
concentrates on a median of only three occasions (range
1-18), and required a median of 2 units (range 0-9) of
packed red cells. The conditoning regimen used did not
influence neutrophil or platelet recovery times.
Other toxicity
Mild oral mucositis was common (WHO grade <3). Alo-
pecia (WHO grade 3) was universal. Nausea was minimal in
patients reciving HDM and was controlled with metoclo-
pramide. More recently, ondansetron 8 mgb.d. was used
with good effect in patients receiving HDM and etoposide.
The median number ofdays on which non-prophylactic anti-
biotics were given was 11 (range 0-23). There were no renal,
hepatic or pulmonary complications, and no patient required
intensive care. Patients stayed a median of 18 days (range
13-41) in hospital post transplant. There was no procedure-
related mortality.
Effect on disease
Actuarial event-free survival from the time of transplant for
all patients considered for ABMT (including the two patients
who relapsed prior to ABMT who were 'taken off at '0'
time) is 83% with a median follow-up of44 months from the
point of tranWlant (Figure 1). Only two very early relapses
post ABMT, at 1 and 2 months, have occurred in the 28
patients transplanted in CR1. In addition, one patient, who
had also had previous Hodgin's disease, died 3 years post
transplant from squamous carcinoma of the lung without
evidence of lymphoma recurrence.
In high-grade NHL patients with advanced disease, the
potential value of high-dose chemotherapy followed by
ABMT has been reported (PhilLps et al., 1984; Gribben et
al., 1989; Petersen et al., 1990). Many centres have used this
form of therapy for patients in relapse or in second or third
remission, and they have used very intensive conditioning
regimens requiring marrow cryopreservation. Additionally,
some centres have used marrow-purging techniques. A reluc-
tance to undertake high-dose therapy with marrow rescue in
first complete remission has been expressed (Gribben et al.,
1987) because of procedure-related mortality rates of around
20% in the larger reported series performed in advanced
disease, and because of the difficulty of proving efficacy in
patients in first complete remission, in whom the prognosis is
more favourable than in patients with advanced disea.
The effiacy, low procedural morbidity, absent mortality
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opreserved ABMT in patients with acute lymphoblastic with high-grade NHL were perceived to be at high risk of
kaemia (Proctor et al., 1988) prompted this phase II study relapse following conventional therapy using criteria similar
NBMT in NHL patients in first CR (some of whom have to those identified by Coleman et al. (1986). Although the
ady been reported; Carey et al., 1991). These patients conditioning regimen was not severely toxic, it was likely to
have useful activity against minimal residual disease in
patients with high-grade NHL in first remission.
In this study there were no procedural deaths and the
procedure-related morbidity was very low. Neutrophil and
1 I I I II "platelet recovery was more rapid than that reported using
cryopreserved autologous marrow rescue (Anderson et al.,
1987; Hill et al., 1989; To et al., 1992), and neutrophil
recovery (without growth factor support) was similar to rates
reported with peripheral blood stem cell (PBSC) harvest
techniques (Kessinger et al., 1989; Bender et al., 1992; Brice
et al., 1992; To et al., 1992; Pettengell et al., 1993). Platelet
60 recovery (> 50 x I0'1') was slower than rates reported with
PBSC harvest techniques (Pettengell et al., 1993), but platelet
transfusion requirements were similar. Unlike PBSC rescue
procedures, the use of non-ryopreserved marrow has the
merit of being a simple, effective and inexpensive form of
40 rescue procedure following high-dose chemotherapy with no
requirement for expert technical assistance or sophisticated
equipment. The drawback to the approach is the limitation
of the use of preconditioning agents with a short half-life, i.e.
melphalan or etoposide, and the need to utilise TBI schedules
20 - in which delivery is complete within 24 h.
The role of first remission intensification using either mar-
row or PBSC rescue in intermediate and high-grade non-
Hodgkin's lymphoma has been studied infrequently to date.
I I In January 1994 the European Bone Marrow Transplant
0 20 40 6 Registry (EBMT) database contained only 300 cases reported
from 65 centres, including the 28 patients in the present Time (months) study. In an assessment of 102 patients on the EBMT regis-
gure 1 Event-free survival of patients with high-risk, high- try with Work-ing Formulation 'high-grade' characteristics
ade NHL referred for autologous bone marrow transplantation and transplanted in first remission, Sweetenham et al. (1994)
first complete remission. *Patient 7 died in first complete demonstrated an overall survival of 70% and progression-
mission at 33 months of carcinoma of the bronchus. free survival of69%. This patient group had a heterogeneous
Tal H Patient characteristics at diagnosis
Disease ECOG
Patient histological type Additional risk performance
no. Age Sex (Kiel) Stage LDH factors status
1 46 F B centroblastic IIIB Raised b 3
2 45 F Centroblastic IIIB ND b 2
3 26 F Immunoblastic IVB ND 3
4 41 F Centroblastic IB ND CNS disease 3
5 24 F Lymphoblastic IVB ND 3
6 53 M T centroblastic IIIB Normal 4
7 58 M Centroblastic IIIA Normal Previous HD 3
8 36 M Centroblastic IIB ND b 3
9 25 M Centroblastic IIB ND b 4
10 41 M Centroblastic IVB ND b 3
11 54 M Centroblastic IIIB ND b 3
12 38 M Centroblastic IILA Normal b 2
13 21 M Immunoblastic IVB ND 3
14 44 F Centroblastic IIIA ND BM 4
15 29 M Centroblastic IIIB ND b 4
16 30 M T lymphoblastic IVB Raised BM 2
17 50 M B lymphoblastic ITIB ND 2
18 26 M B lymphoblastic [VA ND 2
19 33 F B lymphoblastic IVB ND 4
20 38 F T lymphoblastic IVA ND 2
21 16 M B lymphoblastic IIA Raised b 3
22 39 M B lymphoblastic IVA ND 2
23 39 M T lymphoblastic IVA ND 3
24 49 M Centroblastic IVA ND 3
25 41 M Centroblastic TVB ND b 2
26 34 M Centroblastic IIB Raised b 2
27 32 F T immunoblastic IIIA ND b 4
28 30 M Centroblastic IIIB Raised b 2
29 27 M B lymphoblastic IVB R 30 24 M B lymphoblastic~ ~ Relapsed pnior to planned BMT 30 24 M B lymphoblastic IVB
All lymphoblastic non-Burkitt type. ND, not done; BM, bonemarrow disease; b,bulkydisease; T, Tcell;
B, B cell. All patients in this series fulfilled the Kiel histological classification ofhigh grade non-Hodgkin's
lymphoma, which includesdiffusecentroblastic disease. The 16patientswithcentroblasticdiseasewithinthe
Working Formulation classification would be considered intermediate grade.
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form of preconditioning, neverthels the trend of improved
event-free survival for such difficult patients remains en-
couraging. Other single-centre studies with similar patient
populations to the present study have been performed utilis-
iDgmore ablative chemotherapy regimens and marrow purg-
ing in some studies (Philip et al., 1988; Colombat et al., 1990;
Nademanee et al., 1992; Freedman et al., 1993). All these
studie have provided encouraging data and included sub-
stantial proportions of intermediate NHL according to the
Working Formulation as in the present study. The Stanford
study on 20 patients reports an 84% disease-free survival at 3
years when transplanted in first CR (Nademanee et al.,
1992). Philip et al. (1988) and a series from the Dana Faber
Cancer Centre (Freedman et al., 1993) reported similar pro-
mising results. The only substantial trial of autologous
transplant in first CR versus intensive chemotherapy is that
performed by the French National Lymphoma Group, and
preliminary data presented at the American Society of
Haematokogy Meeting in December 1993 (Haioun et al.,
1993) indicated that in a formal trial setting well-dlivered
aggressive chemotherapy consolidation is equivalent to auto-
transplant intensification in first CR.
With a median follow-up ofnearly 4 years following trans-
plant, the event-free survival of 83% in this group of 'high-
risk', high-grade NHL patients considered for ABMT in first
complete remission suggests that this may be a useful con-
solidation therapy following rmission induction chemo/
radiotherapy. Recently a number of indices have been
developed to deineate poor-prognosis groups in patients with
NHL (Hayward et al., 1991; The International Non-
Hodgkin's Lymphoma Prognostic Factors Project, 1993).
One index has been developed and validated by the SNLG
(Hayward et al., 1991) on patients treated with the same
remission induction chemotherapy as in this study. This
anlysis higighted age, stage, performance status, abnormal
white cell count, extranodal diseas and B symptoms as risk
factors. In our group of patients, seven were low risk, six
were intermediate risk and 17 were high risk with predice 5
year survivals of 54%, 31% and 11% respetively. It should
be noted that our patiets in the low/intermediate prognostic
groups had either stage IV or bulk disease, regarded by other
groups as independent indicators of poor prognosis.
As this study commenced 9 years ago the lactate dehyd-
rogenase, a universally accepted and powerful prognostic
factor, was not ahlays measured at diagnosis (see Table II).
Despite not always being able to add this additional risk
factor, 22 of our patients were in the high and
high-intediate risk groups with the remaining eight
patients in the low-intermediate prognostic group according
to the International Non-Hodgkin's Lymphoma Prognostic
Factors Project (The International Non-Hodgkin's Lym-
phoma Prognostic Factors Project, 1993). The 5 year relapse-
free survival rates after achieving complet remission for
these groups according to the project were 46%, 32% and
66% respectively.
We have shown that ABMT without cryopresevation is a
safe procedure which ments further study in patients with
high-risk, high-grade NHL in first complete remission and, as
a result of this pilot information, a prospectiv randomised
controlled study comparing ABMT with no consolidation
therapy in this group of patients is currently in progress
under the auspcs of the SNLG. Similar studies in patients
in first remission are planned by groups in Europe using
more intensive conditioning regimens such as BEAM
(BCNU, etoposide, cytosme arabinoside and melphalan). The
well-documented mortality and toxicity of these regimens
have given rise to misgivings about such an approach being
ethial in first complete remisson. Our data suggest that a
good clinical outcome can be seen following less aggressive
intensification. Apart from the two early relapses (2 months
post ABMT) no patients undergoing this form of intensifi-
cation have relapsed. The paucity of late relapses in this
study provides strong evidence that more ablative and
therefore more toxic regimens may not be necessary to condi-
tion patients with poor-prognosis high-grade NHL in CR1
for ABMT.
If the promising results of this phase II study are borne
out in the prospective randomised study, this may well point
the way for a more effective and less toxic treatment of
patients with high-risk, high-grade, non-Hodgkdn's lym-
phoma.
Note Individual lymphoma groups interested in possible
collaboration utiising an approach of intensification as part
of a randomised trial of the Scotland and Newcastle Lym-
phoma Group should contact Professor SJ. Proctor, Depart-
ment of Haematology, Royal Victoria Infirmary, Queen Vic-
toria Road, Newcastle upon Tyne, NEI 4LP (Tel:
091 232 5131 ext. 24261, Fax 091 2300651).
The authors would hke to thank Dr M.M. Reid for his helpful
reading of the manuscnpt and Mrs Margaret Graham for her excel-
lent secretarial support.
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